HIV 1/2 (ICT) at Dr. Essa Lab

HIV 1/2 (ICT) at Dr. Essa Lab

The HIV 1/2 (ICT) test at Dr. Essa Lab is a rapid, qualitative screening assay designed to detect antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) in human blood, serum, or plasma. Dr. Essa Laboratory & Diagnostic Centre, a trusted name in diagnostic pathology across Pakistan, utilizes advanced immunochromatographic technology to deliver highly accurate screening results. This test plays a critical role in the early identification of HIV infection, allowing for timely clinical intervention and management. The Human Immunodeficiency Virus targets the body’s immune system, specifically CD4 cells, which are vital for fighting off infections. Left untreated, HIV can progress to Acquired Immunodeficiency Syndrome (AIDS). HIV-1 is the most common type found globally, while HIV-2 is less common and primarily concentrated in West Africa, though cases are identified worldwide due to global travel.

The ICT method, often referred to as a rapid diagnostic test, works on the principle of lateral flow immunochromatography. When a patient’s blood sample is applied to the test device, it migrates along a membrane. If antibodies to HIV-1 or HIV-2 are present in the sample, they bind to specific recombinant HIV antigens conjugated with colloidal gold or other colored particles. This antigen-antibody complex then binds to immobilized HIV antigens in the test window, producing a visible colored line. A control line must always appear to validate the test’s procedural integrity. This screening test is highly valued for its rapid turnaround time, simplicity, and high sensitivity, making it an indispensable tool in clinical settings, emergency departments, and routine health screenings.

Clinical Procedure: What to Expect

Patient Preparation

Preparing for an HIV 1/2 (ICT) test at Dr. Essa Lab is straightforward and requires minimal effort from the patient. Unlike certain metabolic or biochemical panels, fasting is not required for this test; patients can eat and drink normally before their appointment. It is essential to inform the healthcare provider or phlebotomist of any ongoing medical treatments, particularly immunosuppressive therapies, recent vaccinations, or blood transfusions, as these can occasionally influence immunological responses. Patients should also disclose if they are taking pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), as these medications can affect antibody production timelines. Psychological preparation is equally important; undergoing an HIV test can cause anxiety, and patients are encouraged to speak with a counselor or healthcare provider at Dr. Essa Lab if they require pre-test counseling to understand the implications of the test results.

During the Procedure

The procedure for collecting a sample for the HIV 1/2 (ICT) test is a standard venipuncture, performed by highly trained phlebotomists at Dr. Essa Lab. The patient is comfortably seated, and the phlebotomist identifies a suitable vein, typically in the antecubital fossa (the inner bend of the elbow). The skin over the selected site is thoroughly cleansed with an antiseptic swab (usually 70% isopropyl alcohol) to prevent contamination and minimize the risk of infection. A tourniquet is applied to the upper arm to increase venous pressure, making the vein more visible and accessible. A sterile, single-use needle is gently inserted into the vein, and a small volume of blood is drawn into a vacuum collection tube. Once the sample is collected, the needle is carefully withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze to promote hemostasis. An adhesive bandage is then applied. The entire collection process takes less than five minutes and involves minimal discomfort, often described as a brief pinch. The collected sample is immediately labeled with the patient’s unique identification details to ensure absolute traceability and prevent cross-contamination.

When is an HIV 1/2 (ICT) Performed?

Screening Following Potential High-Risk Exposure

Physicians frequently order the HIV 1/2 (ICT) test when a patient has experienced potential exposure to the virus. High-risk exposures include unprotected sexual contact with an individual of unknown HIV status, sharing needles or syringes during intravenous drug use, or accidental occupational exposure, such as a needlestick injury among healthcare workers. Because the ICT test detects antibodies rather than the virus itself, it is crucial to consider the window period—the time between exposure and the development of detectable antibodies, which typically ranges from 3 to 12 weeks. If a test is performed too early during this window, it may yield a false-negative result, necessitating repeat testing at a later date to confirm the patient’s status.

Routine Antenatal and Prenatal Care

Screening for HIV is a standard and vital component of routine antenatal care for all pregnant women. Detecting HIV early in pregnancy is critical to preventing mother-to-child transmission (vertical transmission), which can occur during pregnancy, labor, delivery, or breastfeeding. If a pregnant woman is identified as HIV-positive, healthcare providers can immediately initiate antiretroviral therapy (ART). Proper medical management, including viral suppression, planned delivery methods, and avoiding breastfeeding, can reduce the risk of transmitting the virus to the infant to less than one percent. The HIV 1/2 (ICT) test serves as an efficient, rapid first-line screening tool in prenatal clinics.

Pre-Employment and Visa Medical Requirements

Many organizations, government bodies, and international immigration authorities require routine health screenings, including HIV testing, as part of pre-employment medical evaluations or visa application processes. This is particularly common for individuals seeking employment in specific sectors, such as healthcare, food handling, or international corporate roles, as well as those applying for residency or work visas in various countries. Dr. Essa Lab provides certified and confidential testing services that meet the stringent requirements of these regulatory bodies, ensuring that patients receive official, verifiable documentation of their health status.

Investigation of Opportunistic Infections and Unexplained Symptoms

When patients present with chronic, unexplained symptoms that suggest an underlying immunodeficiency, clinicians will order an HIV 1/2 (ICT) test. These symptoms may include persistent fever, unexplained weight loss (wasting syndrome), chronic diarrhea lasting more than a month, recurrent night sweats, generalized lymphadenopathy (swollen lymph nodes), or unusual, recurrent infections such as oral thrush (candidiasis) or shingles (herpes zoster). Identifying HIV as the underlying cause of immune suppression is essential for initiating appropriate therapeutic regimens and preventing the development of severe opportunistic infections.

Pre-Surgical and Blood Transfusion Protocols

Prior to undergoing major surgical procedures or receiving blood transfusions, patients are routinely screened for bloodborne pathogens, including HIV-1 and HIV-2. This protocol serves multiple clinical purposes: it ensures the safety of the surgical team by allowing them to take extra precautions against occupational exposure, assists in planning post-operative care and monitoring for potential infectious complications, and maintains the safety of the blood supply chain. While blood donors are screened directly, testing recipients pre-transfusion provides a baseline clinical record of their infectious disease status.

What Does an HIV 1/2 (ICT) Detect?

The HIV 1/2 (ICT) test is designed to detect specific immunological markers and evaluate clinical parameters associated with HIV infection. The test evaluates and detects:

• Antibodies to HIV-1: Specifically targets antibodies produced by the immune system against the envelope glycoproteins (such as gp120, gp41) of HIV-1.
• Antibodies to HIV-2: Specifically targets antibodies produced against the envelope glycoproteins (such as gp125, gp36) of HIV-2.
• IgG Immunoglobulins: Detects long-term antibodies that indicate an established immune response.
• IgM Immunoglobulins: Detects early-stage antibodies that appear shortly after infection.
• Recombinant Antigen Binding: Evaluates the binding affinity of patient antibodies to synthetic viral antigens.
• Systemic Immune Response: Confirms whether the host immune system has recognized and reacted to the viral pathogen.
• Control Line Integrity: Verifies the presence of a functional control band, ensuring the test kit’s reagents are active.
• Sample Migration: Confirms proper lateral flow capillary action across the nitrocellulose membrane.
• Absence of Cross-Reactivity: Evaluates whether non-specific proteins in the blood cause false-positive results.
• Screening Baseline: Establishes a qualitative baseline (reactive or non-reactive) for further diagnostic confirmation.
• Window Period Limitations: Identifies potential false negatives if testing occurs before antibody seroconversion.
• Serum Quality: Assesses whether hemolysis or lipemia in the blood sample interferes with the lateral flow assay.
• Plasma Compatibility: Verifies the test’s performance when utilizing anticoagulated plasma samples.
• Whole Blood Compatibility: Evaluates the test’s ability to filter out red blood cells to allow clear band visualization.
• Specificity for HIV-1 Group M: Detects antibodies against the most prevalent global strains of HIV-1.
• Specificity for HIV-1 Group O: Detects antibodies against rarer outlier strains of HIV-1.
• Specificity for HIV-2 Subtypes: Detects antibodies against various genetic variants of HIV-2.
• Qualitative Reactivity: Determines the visual presence of a test line indicating a positive reaction.
• Qualitative Non-Reactivity: Confirms the absence of a test line, indicating no detectable antibodies.
• Procedural Validity: Ensures the sample volume was sufficient for accurate chromatographic migration.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Laboratory & Diagnostic Centre is renowned for its efficiency and commitment to rapid, accurate reporting. The turnaround time for an HIV 1/2 (ICT) test is typically within a few hours of sample collection, owing to the rapid nature of immunochromatographic assays. Dr. Essa Lab understands the anxiety associated with HIV testing and prioritizes swift processing to minimize patient stress. Once the test is completed and verified by a consultant pathologist, the report is securely uploaded to the Dr. Essa Lab online portal. Patients can access their confidential reports from the comfort of their homes using the unique patient ID and password provided on their receipt. Additionally, reports can be collected in person from any of the numerous Dr. Essa Lab branches across Karachi and other major cities, or received via WhatsApp and email. Dr. Essa Lab maintains strict confidentiality protocols, ensuring that sensitive test results are only disclosed to the patient or authorized healthcare providers.

HIV 1/2 (ICT) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HIV-1 Antibodies	Non-Reactive (No band visible in the HIV-1 test region)	Reactive (Visible band in the HIV-1 test region, indicating potential HIV-1 infection)
HIV-2 Antibodies	Non-Reactive (No band visible in the HIV-2 test region)	Reactive (Visible band in the HIV-2 test region, indicating potential HIV-2 infection)
Control Line (C)	Visible Band (Confirms test validity and proper sample migration)	No Band Visible (Invalid test; requires immediate retesting with a new device)
Specimen Quality	Clear, non-hemolyzed, non-lipemic sample	Hemolyzed, lipemic, or icteric sample (may interfere with visual reading and require recollection)
IgG/IgM Antibody Response	No detectable antibodies against HIV-1 or HIV-2	Detectable antibodies present, suggesting active or past infection
Window Period Status	Test performed outside the window period (accurate negative)	Test performed within the window period (potential false negative despite active infection)
Confirmatory Testing Requirement	Not required if screening is negative and no recent exposure	Required (Western Blot, PCR, or ELISA must be performed to confirm any reactive ICT result)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for HIV 1/2 (ICT)?

• Experienced healthcare professionals and consultant pathologists supervising all diagnostic testing.
• Patient-focused care with a strong emphasis on empathy, respect, and absolute confidentiality.
• Quality diagnostic services backed by rigorous internal and external quality control programs.
• Professional and clear reporting with easy-to-understand results and rapid turnaround times.
• Modern diagnostic approach utilizing state-of-the-art immunochromatographic and molecular technologies.
• Comfortable and hygienic environment across all collection centers to ensure patient safety and peace of mind.
• Convenient locations with an extensive network of branches throughout Karachi and Pakistan.
• Commitment to accurate diagnosis, helping patients and clinicians make informed healthcare decisions.